Genfit S.A. (NASDAQ:GNFT – Get Free Report)’s stock price was down 0.2% during trading on Monday . The stock traded as low as $4.15 and last traded at $4.26. Approximately 8,318 shares traded hands during trading, a decline of 53% from the average daily volume of 17,548 shares. The stock had previously closed at $4.27.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Genfit in a research report on Monday, July 29th.
Check Out Our Latest Report on Genfit
Genfit Price Performance
Institutional Investors Weigh In On Genfit
An institutional investor recently raised its position in Genfit stock. Optiver Holding B.V. increased its position in shares of Genfit S.A. (NASDAQ:GNFT – Free Report) by 2,229.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 82,359 shares of the company’s stock after acquiring an additional 78,823 shares during the period. Optiver Holding B.V. owned approximately 0.17% of Genfit worth $315,000 as of its most recent filing with the Securities and Exchange Commission. 2.24% of the stock is owned by institutional investors and hedge funds.
About Genfit
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Read More
- Five stocks we like better than Genfit
- Stock Splits, Do They Really Impact Investors?
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Basic Materials Stocks Investing
- 2 Option Strategies to Maximize Profits in a Bear Market
- What Are the FAANG Stocks and Are They Good Investments?
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.